Local Anesthetics in Special Populations

Local Anesthetics in Special Populations

Local Anesthetics in Special Populations

On this page

LA in Special Groups - The Ground Rules

  • Altered pharmacokinetics: Expect changes in absorption, distribution (e.g., altered Vd), metabolism (↓ hepatic/renal clearance), and excretion.
  • Altered pharmacodynamics: Nerve sensitivity is often ↑ (e.g., elderly, pregnancy), affecting LA potency/duration.
  • Guiding principles:
    • Adopt "start low, go slow" dosing.
    • Crucial: meticulous monitoring for early CNS/CVS toxicity signs.
    • Proactive dose reduction is key.

⭐ Special populations often have a narrower therapeutic window for LAs, demanding careful titration and heightened vigilance.

Pediatric Patients - Tiny Patients, Big Care

  • Pharmacokinetic Differences:
    • ↑ Volume of distribution (Vd) (larger Extracellular Fluid).
    • ↓ Protein binding (esp. neonates due to ↓ alpha-1-acid glycoprotein) → ↑ free drug fraction.
    • ↓ Hepatic metabolism (immature P450 enzymes).
    • ↓ Renal excretion (immature Glomerular Filtration Rate).
  • Increased Toxicity Risk:
    • Higher susceptibility to systemic toxicity.
    • ⚠️ Prilocaine/Benzocaine: Risk of methemoglobinemia (avoid in infants <6 months).
  • Maximum Recommended Doses (mg/kg):
    AnestheticPlainWith Epinephrine
    Lidocaine3-55-7
    Bupivacaine1.5-22-2.5
    Ropivacaine2-32-3

⭐ Neonates exhibit decreased levels of alpha-1-acid glycoprotein, leading to a higher free fraction of local anesthetics and an increased risk of toxicity.

Geriatric Patients - Golden Years, Gentle Doses

  • Physiological Considerations:
    • Reduced organ function (hepatic, renal) → ↓ LA clearance, ↑ half-life.
    • Decreased lean body mass, increased body fat → ↑ volume of distribution for lipid-soluble LAs.
    • Altered protein binding (↓ albumin) → ↑ unbound, active LA.
    • Increased sensitivity of nervous tissue.
    • Polypharmacy → potential drug interactions.
  • Pharmacokinetic Changes:
    • Slower onset of action.
    • Longer duration of effect.
  • Dosing Strategy: Reduce dose by 20-50%. Titrate slowly.

⭐ Geriatric patients show increased susceptibility to CNS toxicity (e.g., confusion, agitation) and cardiotoxicity from LAs.

Pregnancy & Lactation - Two Lives, One Plan

Physiological changes: ↑ CO, ↑ GFR, ↑ Vd; ↓ protein binding (↑ free drug).

  • ⚠️ Increased sensitivity to LA neurotoxicity & cardiotoxicity (e.g., Bupivacaine).

Placental Transfer:

  • Factors: ↑ lipid solubility, ↓ ionization, ↓ protein binding, ↓ molecular weight (📌 LIMP).
  • Ion trapping: Fetal acidosis traps LAs (weak bases) in ionized form. $pH - pKa = log([A^-]/[HA])$.

⭐ Progesterone increases neuronal sensitivity to local anesthetics during pregnancy.

LA Safety Profile:

SettingPreferred LAsNotes
Labor AnalgesiaBupivacaine, RopivacaineEpidural/spinal; monitor for toxicity
LidocainePerineal infiltration
LactationLidocaine, Bupivacaine, RopivacaineGenerally safe; low milk excretion

Co-morbid Conditions - Tricky Terrains

Co-morbidityLA Choice & Dose AdjustmentKey Precautions & Monitoring
Hepatic DiseaseAmides (e.g., lidocaine): ↓ dose due to impaired metabolism.Monitor for CNS/cardiac toxicity. Esters preferred in severe disease.
Renal DiseaseRepeated doses: caution. Risk of active metabolite accumulation.Monitor for systemic toxicity, esp. with mepivacaine, prilocaine.
Cardiac Disease↓ LA dose. Limit/avoid epinephrine with arrhythmias/ischemia.Arrhythmogenic potential. Continuous ECG. Careful vasoconstrictor use.
Respiratory DiseaseHigh neuraxial/interscalene blocks: use cautiously.Risk of phrenic nerve palsy, respiratory depression. Monitor ventilation.
Pseudocholinesterase Def.Esters (procaine, tetracaine): avoid or drastically ↓ dose.Prolonged LA effect/paralysis. Prefer amides. Monitor neuromuscular function.

High‑Yield Points - ⚡ Biggest Takeaways

  • Pregnancy: Bupivacaine has ↑ cardiotoxicity; Lidocaine (Cat B) safer. Avoid high-dose Prilocaine (methemoglobinemia).
  • Pediatrics: Neonates: ↓ AAG, immature liver. Use precise weight-based dosing. Max lidocaine 4.5 mg/kg.
  • Geriatrics: ↓ clearance necessitates LA dose reduction (e.g., 20-50%).
  • Severe Liver Disease: Reduce amide LA dose significantly; ester LAs are safer.
  • Renal Failure: Amide LA dose often unchanged; active metabolites may accumulate.
  • Pseudocholinesterase Deficiency: Avoid ester LAs (prolonged action); prefer amides.
  • Obesity: Dose LAs based on Ideal Body Weight (IBW) to prevent toxicity.

Practice Questions: Local Anesthetics in Special Populations

Test your understanding with these related questions

The anesthetic agent which can cause massive hepatic necrosis?

1 of 5

Flashcards: Local Anesthetics in Special Populations

1/10

Highest blood concentrations of local anesthetic are seen after IV injection f/b _____ injection

TAP TO REVEAL ANSWER

Highest blood concentrations of local anesthetic are seen after IV injection f/b _____ injection

tracheal

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial